Abstract 191P
Background
Gastric cancer (GC) is a major global health concern, with prognosis influenced by tumor stage and its microenvironment, especially immune cell presence. This research investigates the relation between CD8 T cell expression, emphasizing CXCR6, and GC survival outcomes.
Methods
Using TCGA-STAD RNA-seq data, we studied a cohort of 280 Stage 2 and 3 GC patients. CD8 T cell expression was examined through X Cell Analysis, followed by Cutoff Determination via R package Maxstat. Post categorization into CD8L and CD8H groups, Differential Gene Expression Analysis identified 495 upregulated and 102 downregulated genes. Weighted Gene Co-expression Network Analysis highlighted CXCR6's importance. Correlations between CXCR6, immune cell infiltration, and survival patterns were explored. Verification came from GES 62254 data and Immunohistochemical Staining of a sample from Dong-A University Hospital.
Results
The findings reveal that heightened CXCR6 expression is significantly associated with improved survival outcomes in both recurrence-free survival (RFS) and overall survival (OS) using TCGA-STAD data. Importantly, the validation using GES 62254 data consistently supports these results. Moreover, the study delves into the tumor microenvironment using TCGA-STAD RNA-seq data, showcasing a positive link between CXCR6 expression and immune cell presence, particularly CD8 T cells, T cell gamma delta cells, NK cells, and activated DCs. This suggests a potential reinforcement of anti-tumor responses. The research further uncovers correlations between CXCR6 expression and markers of CD8 T cell activation, as well as the activation of DCs.Importantly, a clinical investigation involving GC patients treated at Dong-A University Hospital supports the statistical significance of increased CXCR6 expression in relation to enhanced survival rates.
Conclusions
Our research showcases the relationship between enhanced CXCR6 expression and improved GC patient survival. It presents CXCR6 as a potential prognostic biomarker, underscoring its role in the tumor immune milieu. The focus on CD8 T cells and immune pathways suggests promising therapeutic directions, marking a step toward precision-based GC interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
National foundation of Korea grant.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract